References
1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020;73(5):1170-1218. DOI: 10.1016/j.jhep.2020.08.018
2. Morales-Arraez D, Nieto Bujalance Y, Diaz-Flores F, et al. Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2020;32(4):528-534.
3. WHO. Global health sector strategy on viral hepatitis 2016–2021, Towards ending viral hepatitis. Geneva, Switzerland: World Health Organization June; 2016.
4. Plan Estratégico para el abordaje de la Hepatitis C en el SNS (PEAHC). Ministerio de Sanidad, Consumo y Bienestar Social. October 2020. Available in: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/Plan_Estrategico_Abordaje_ Hepatitis_C_(PEAHC).pdf.
5. Crespo J, Albillos A, Buti M, et al. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Rev Esp Enferm Dig. 2019;111(11):862-873. DOI: 10.17235/reed.2019.6700/2019
6. Razavi H, Sanchez Gonzalez Y, Yuen C, et al. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40(3):522-529.
7. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet 2020;395:1015-1018.
8. Crespo J, Iglesias-García J, Hinojosa Del Val JE, et al. COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. Rev Esp Enferm Dig. 2020;112(5):389-396.
9. Crespo J, Fernández Carrillo C, Iruzubieta P, et al. Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. J Gastroenterol Hepatol. 2021;36(6):1627-1633.
10. Sperring H, Ruiz-Mercado G, Schechter-Perkins EM. Impact of the 2020 COVID-19 Pandemic on Ambulatory Hepatitis C Testing. J Prim Care Community Health. 2020;11:2150132720969554.
11. Kaufman HW, Bull-Otterson L, Meyer WA 3rd, et al. Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. Am J Prev Med. 2021;61(3):369-376.
12. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31-36.
13. Buti M, Domínguez-Hernández R, Casado MA. Impact of the COVID-19 pandemic on HCV elimination in Spain. J Hepatol. 2021;74(5):1246–8.
14. Gómez L, Reygosa C, Morales-Arráez DE, et al. Diagnostic test accuracy of the cobas 6800 system for detection of hepatitis c virus viraemia levels from dried blood spots. Enferm Infecc Microbiol Clin (Engl Ed). 2020;38(6):267-274.
15. Morales-Arraez D, Hernández-Bustabad A, Medina-Alonso MJ, et al. Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. Int J Drug Policy. 2021;94:103235.
16. Rehman ST, Rehman H, Abid S. Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C. World J Hepatol. 2021;13(7):781-789.
17. Frost MC, Sweek EW, Austin EJ, et al. Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S. AIDS Behav. 2021:1–12.
18. Blach S, Blomé M, Duberg AS, et al. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. Liver Int. 2021;41(9):2024-2031.
19. Lopes H, Baptista-Leite R, Franco D, et al. Fighting Hepatitis C in a COVID-19 ecosystem. Public health policies are needed more than ever. J Gastrointestin Liver Dis. 2020;29(4):692-693.
20. Crespo J, Díaz-González Á, Iruzubieta P, et al. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. J Hepatol. 2021;74(4):966-967.
21. Giacomelli A, Pagani G, Conti F, et al. Detecting HCV infection by means of mass population SARS-CoV-2 screening: A pilot experience in Northern Italy. J Hepatol. 2021;75(2):484-486.
22. Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay. J Clin Virol. 2021;136:104739.
23. Mendlowitz AB, Naimark D, Wong WWL, et al. The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. Liver Int. 2020;40(6):1282-1291.
24. Burgui C, Martín C, Aguinaga A, et al. Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019. Rev Esp Enferm Dig. 2021;113(1):28-34. DOI: 10.17235/reed.2020.7000/2020
25. Cuadrado A, Cobo C, Mateo M, et al. Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. Int J Drug Policy. 2021;88:103031.
26. Mangia A, Albanese AP, Bourliére M, et al. Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. Adv Ther. 2021;38(3):1397-1403.